KeyBanc lowered the firm’s price target on Recursion Pharmaceuticals to $12 from $16 and keeps an Overweight rating on the shares. The firm’s credit card data continues to show healthy utilization levels across hospital systems post the Change Healthcare outage, with hospital customer levels up high single digits in May and June year over year, but the ongoing robust employment data for healthcare systems keeps the firm wary of potential spending for hospital-exposed names, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXRX:
- Cathie Wood’s ARK Investment bought 143K shares of Recursion Pharmaceuticals
- Cathie Wood’s ARK Investment bought 423K shares of Recursion Pharmaceuticals
- AI Could Revolutionize Drug Discovery: A Look at Key Players
- Cathie Wood’s ARK Investment bought 505K shares of Recursion Pharmaceuticals
- Cathie Wood’s ARK Investment bought 204K shares of Recursion Pharmaceuticals